Skip to main content
SYRE
NASDAQ Life Sciences

Spyre Posts $96.1M Q3 Loss, Expands HS Program With $1.5B Pro Forma Cash

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$99.73
Mkt Cap
$9.162B
52W Low
$21.145
52W High
$110.175
52W Position info
372% above low
Off High info
9.5% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SYRE has more than doubled off its 52-week low of $21.145.

Summary

Spyre's Q3 net loss widened to $96.1 million from $11.2 million a year ago as R&D spending nearly doubled to $89.2 million on manufacturing and trial costs. The company ended September with $1,071.9 million in cash and securities, and $1,467.9 million pro forma for the October offering and ATM sales, funding operations into the second half of 2029. On the pipeline, SPY072 missed its primary endpoints in the PsA and axSpA sub-studies and will not advance in rheumatic disease, but Spyre is redirecting the TL1A asset into a new Phase 2 SKYLIGHT trial in hidradenitis suppurativa, backed by the $400 million-plus October raise. SKYLINE Part B is enrolling ahead of schedule, letting Spyre raise the enrollment target for three combination arms with induction data now expected in Q3 2027. The cash position removes near-term financing risk; the read is mixed on data, with the rheumatic disease failure offset by the HS pivot and faster IBD combination enrollment.

At the time of this announcement, SYRE was trading at $99.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $21.15 to $110.18. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

SYRE - Latest Insights

SYRE
Nov 03, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $97.63 info
Change: -$2.10 (-2%) info
Market Cap: $9.272B info
SYRE
Oct 07, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $80.51
Real-time Price: $97.63 info
Change: +$17.12 (+21%) info
Market Cap: $9.272B info
SYRE
Oct 06, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $80.11
Real-time Price: $97.63 info
Change: +$17.52 (+22%) info
Market Cap: $9.272B info
SYRE
Oct 06, 2026, 11:53 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $81.16
Real-time Price: $97.63 info
Change: +$16.47 (+20%) info
Market Cap: $9.272B info
SYRE
Oct 05, 2026, 4:03 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $89.81
Real-time Price: $97.63 info
Change: +$7.82 (+9%) info
Market Cap: $9.272B info